RxDoctor Payments Data

George Graves, MD

Internal Medicine · Chevy Chase, MDNPI 1104919133

Payments from drug & device makers

$2,248in general payments, 2019–2025

Across 115 payments — averaging $19.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$382
  • Pfizer$341
  • Amgen$249
  • Novo Nordisk$138
  • Astellas Pharma US Inc$136
  • Amarin Pharma, Inc.$124
  • plus $878 from 27 others

What the payments were for

  • Food & beverage$2,248100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,248 in reported general payments places this provider in the 80th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$171,073
Medicare patients
725
Services billed
1,859

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban50$63,401
MounjaroTirzepatide55$57,723
Atorvastatin Calcium511$7,322
SynthroidLevothyroxine Sodium92$7,310
Rosuvastatin Calcium261$5,260
Olmesartan Medoxomil131$4,098
Levothyroxine Sodium233$3,438
Nebivolol Hcl43$3,132
Zolpidem Tartrate190$2,626
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide54$2,325
Amlodipine Besylate217$2,218
Metoprolol Succinate127$2,205
Irbesartan48$2,202
Irbesartan-HydrochlorothiazideIrbesartan/Hydrochlorothiazide36$1,998
Ezetimibe59$1,429

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$341$63,40150 claims
Lilly USA, LLCMounjaro$48$57,72355 claims
AbbVieSynthroid$382$7,31092 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Chevy Chase

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →